These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304 [TBL] [Abstract][Full Text] [Related]
9. Antifibrillatory efficacy of concomitant beta adrenergic receptor blockade with dilevalol, the R,R-isomer of labetalol, and muscarinic receptor blockade with methylscopolamine. Lynch JJ; Nelson SD; MacEwen SA; Driscoll EM; Lucchesi BR J Pharmacol Exp Ther; 1987 May; 241(2):741-9. PubMed ID: 2883307 [TBL] [Abstract][Full Text] [Related]
10. Effects of diltiazem upon experimental ventricular dysrhythmias. Patterson E; Eller BT; Lucchesi BR J Pharmacol Exp Ther; 1983 Apr; 225(1):224-33. PubMed ID: 6834274 [TBL] [Abstract][Full Text] [Related]
11. Comparative beta-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs. Gomoll AW; Bartek MJ Eur J Pharmacol; 1986 Dec; 132(2-3):123-35. PubMed ID: 2880732 [TBL] [Abstract][Full Text] [Related]
12. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331 [TBL] [Abstract][Full Text] [Related]
14. Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]. Lynch JJ; Wallace AA; Stupienski RF; Baskin EP; Beare CM; Appleby SD; Salata JJ; Jurkiewicz NK; Sanguinetti MC; Stein RB J Pharmacol Exp Ther; 1994 May; 269(2):541-54. PubMed ID: 7802864 [TBL] [Abstract][Full Text] [Related]
15. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs. Sen L; Cui G; Sakaguchi Y; Singh BN J Pharmacol Exp Ther; 1998 May; 285(2):687-94. PubMed ID: 9580614 [TBL] [Abstract][Full Text] [Related]
16. Differential efficacy of the class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction. Lynch JJ; Wallace AA; Stump GL; Stupienski RF; Kothstein T; Gehret JR J Pharmacol Exp Ther; 1996 May; 277(2):671-8. PubMed ID: 8627544 [TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic and electrophysiologic actions of CK-3579 and sematilide in a conscious canine model of sudden coronary death. Chi LG; Mu DX; Driscoll EM; Lucchesi BR J Cardiovasc Pharmacol; 1990 Aug; 16(2):312-24. PubMed ID: 1697389 [TBL] [Abstract][Full Text] [Related]